NEW Analyst Apple Price Target at $900 and 4 Stock Insights to Watch Now
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares are expected by Piper Jaffray to continue to rally into the Phase I data on NS5A inhibitor ACH-3102 in hepatitis C virus genotype 1 patients later in the month. Also, Piper still expects consolidation in the hepatitis C space to continue with Achillion as a possible target. The firm keeps an Overweight rating on the stock with a $16 price target.
Don’t Miss: Apple-nomics Trickles Down to Semiconductors.
United Natural Foods, Inc. (NASDAQ:UNFI) reported in-line EPS but provided lower FY13 EPS guidance than expected, causing BMO Capital to believe that the company’s guidance remains conservative, and the firm expects the company’s gross margin pressure to ease. The firm keeps an Outperform rating.
McKesson Corporation (NYSE:MCK): According to Cowen, McKesson should have limited downside risk in the near-term due to underlying fundamentals, conservative guidance, and its track record of being the best performing drug distributor over the past two years. Cowen notes that the shares are near all-time highs and valuation could be ahead of itself, but the fimr maintains its Outperform rating.
Apple Inc. (NASDAQ:AAPL) price target has been increased by Hudson Square to $900 from $700 due to its expanding addressable market. Shares have a Buy rating.
Apple Inc. (NASDAQ:AAPL): Following the evaluation of Apple’s smartphone competitors, JMP Securities thinks that that the iPhone 5 may could the top smartphone, but that the gap between Apple and its competitors will probably to narrow. The firm keeps a Market Perform rating on the stock.
Don’t Miss: Apple DOMINATES Mobile Ads.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>